)

// : // :

The study of adverse drug reaction to streptokinase in inpatients with acute myocardial infarction in shahid madani hospital for cardiovascular disease in tabriz between 1999 and 2001

*Garjani A., Abedinoghli Kh., Shamsmohammadi M., salimnezhad M., Maleki N. School of Pharmacy, Tabriz University of Medical Sciences

Received: 2004/8/25, Accepted: 2005/5/15

OBJECTIVES: Streptokinase is a protein produced by β-hemolytic Streptococci. It has no intrinsic enzymatic activity, but it forms a stable complex with plasminogen, which converts plasminogen to plasmin. It is administrated in the management of deep vein thrombosis, arterial thrombosis and embolism, pulmonary embolism, acute evolving transmural myocardial infarction and occluded AV (Atrial-Ventricular) cannula. The common allergic reactions include urticaria, itching, headache, musculoskeletal pain, flushing, nausea, fever, bronchospasm, and anaphylactic reactions. The hematological side effects are bleeding (involving the GI tract, GU tract), unstable tension, atrial or Ventricular disarrhythmias. **METHODS:** In this retrospective study, the questionnaires were completed for all 332 inpatients that had received streptokinase during 1999-2001. According to data from patient's files the questionnaire were filled. **RESULTS:** Among 332 patients received streptokinase, 76.81% was male and 22.89% was female, that 18.97% of males and 4.21% of females showed side effects. Incidence of side effects was 10.47% in 1999, 10.74% in 2000 and 50% in 2001. The incidence of side effects in 2001 was varied and high. Most of the side effects were allergic reactions. The source of streptokinase during that time was Cuba under trade name of Heberkinase. **CONCLUSION:** These results may indicate that the used batches in 2001 were different from previous and probably contained more impurities. **Keywords:** Myocardial Infarction, Streptokinase, Side effects.


*Corresponding Author: Dr. Alireza Garjani, Professor, School of Pharmacy, Tabriz University of Medical Sciences,

Tel: 3372250; Fax: 3344798; E-mail: garjania2002@yahoo.com

۲٦

(severe) % .() .()) (.() malignancy .() Fishers exact test p<0.05 % Heberkinase % / 60 50 لرصد وقوع عارضه جائبي 40 () 30 20 10.47 10.74 10 0. 79 80 78 سال .() (Heberkinase) *p<0.001. (moderate) (mild)

TY



www.SID.ir

Heberkinase

6- References

- Sirtori C. Clinical medicine series, MCGraw-Hill, London, 2000, 767
- Zhang, X. W., Sun, T., Huang, X. N., et al, Recombinant streptokinase production by fed batch cultivation of escherichia coli, Enzyme Microb, Technol. 1999, 24, 647-50.
- Technol, 1999, 24, 647-50.
 Majerus, P.W., Broze, G.j. and Miletich J. P. Anticoagulant thrombolytic and antiplatelet drugs, In: Goodman & Gilmans: the pharmacological basis of therapeutics, Hardman, J. G., Limbird, L. E., Molinoff, P.B., et al. 9 th ed., MCGraw -Hill, NewYork, 1996,1351-53.
- Callahan K., Blood S., fluids, electrolytes and hematological drugs, In: Remington: the science and practice of pharmacy, Gennaro, A. R., 20 th ed., Philadelphia collage of pharmacy and science, Philadelphia, 2000, 1258.



- louis St. Drug facts and comparisons, 55 th ed., Fact and comparisons, 2001, 196-99.
- 6. Stephans, M. D. B., Talbot, J. C. C. and Routledge. P.A. Detection of new advers drug reaction, 4 th ed., Macmillan, U. K., 2000, 11, 40, 42, 33-35.
- 7. Wade O.L. and Beeley, L. Advers reactions to drugs, 2th ed., London, 1996, 10.
- Davies, D.M. Textbook of advers drug reactions, 1st ed., New York, Oxford University Press., 1987, 115.
- Tsang, T. S. M., Califf, R. M., Stebbins, A. L., et al., Incidence and impact on out come of Streptokinase allergy in the Gusto-1 trial, The American Journal of cardiology, 1997, 79: 1232-35.
- Connes C.L., Demaria, A.N. Optimal Utilization of thrombolytic therapy for acute myocardial infarction. Concepts and controversies. Journal of Am. Coll. Of Cardiology. 1990, 16 (1): 223-31.